ASX:MDC

Medlab Clinical (MDC) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
36,677 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
MDC stock logo

About Medlab Clinical Stock (ASX:MDC)

Medlab Clinical Limited, a biotechnology company, researches, develops, and pre-commercializes pharmaceutical and nutraceutical products in Australia. Its drug candidate includes NanaBis, a buccal spray from cannabis oil extract for oncology and pain management; and NanoCBD, a buccal spray from hemp oil extract for mental health. The company also develops NanoCelle, a patented sub-micron drug delivery platform that allows passive diffusion of active pharmaceutical ingredients directly into the bloodstream through oral-buccal, sublingual, intranasal, and transdermal or topical delivery. In addition, it offers virtual clinic services. The company was founded in 2012 and is headquartered in Botany, Australia.

MDC Stock News Headlines

Clinical Laboratory Technician Salary
The Best AI Stock to Own in the World Today is Trading for Just $25
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
Just Released: Insider's Secret to Trading Options
This Surprisingly Simple Formula Can Double Your Money Collecting Consistent Profits From The Stock Market Is More Accessible Than You Think A small group of individuals are using a legitimate yet rarely discussed strategy to generate income from the stock market. They're NOT day traders. And they're NOT Wall Street suits either. I'm talking about normal "working stiffs" and retirees generating steady income from a source that 99% of investors completely overlook. This overlooked income source can be yours today.
Medlab Clinical Ltd. Files to List on Nasdaq
Medlab Clinical Ltd
M.D.C. Holdings, Inc. (MDC)
Miami Dade College User Reviews
Nanocelle® Patent Granted in Usa
NANOCELLE “ISSUE OF ALLOWANCE” BY US PATENT OFFICE
Medlab Clinical Ltd (MDC)
Medlab Clinical Limited (MDC.AX)
See More Headlines
Receive MDC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medlab Clinical and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
1,773
Year Founded
N/A

Profitability

Net Income
$-8,920,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.66 million
Book Value
A$1.42 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.90
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Dr. Sean Michael Hall (Age 54)
    MD, CEO & Director
    Comp: $574.11k
  • Mr. Kerem Kaya (Age 51)
    CFO, COO & Company Secretary
    Comp: $292.83k
  • Dr. David A. Rutolo ­ (USA)
    J.D., Ph.D., Director of Science
  • Mr. Ian Curtinsmith
    Chief Information Officer

MDC Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Medlab Clinical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medlab Clinical investors own include iSignthis (ISX), FBR (FBR), Embark Early Education (EVO), Dacian Gold (DCN), Constellation Technologies (CT1), Bod Australia (BDA), Afterpay (APT), Alkane Resources (ALK) and AusCann Group (AC8).

This page (ASX:MDC) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners